Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DANCR siRNA
- Development stage
- Preclinical
- Lead developer
- The Ohio State University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
DANCR siRNA is an experimental, preclinical research compound that utilizes small interfering RNA (siRNA) to silence the long non-coding RNA (lncRNA) known as Differentiation Antagonizing Non-Protein Coding RNA (DANCR). DANCR acts as an oncogene in multiple cancer types, including acute myeloid leukemia (AML), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC), by promoting stemness, epithelial-mesenchymal transition (EMT), and cell proliferation. The siRNA works through the RNA interference (RNAi) pathway to degrade DANCR transcripts. In preclinical studies, it is often delivered via specialized nanoparticle systems, such as transferrin-conjugated or RGD-PEG-ECO nanoparticles, to enhance stability and tumor-specific uptake. While it has shown efficacy in reducing tumor growth and cancer stem cell populations in vivo, it is currently not associated with a specific commercial drug program or clinical trial.
- Other names
- Differentiation Antagonizing Non-Protein Coding RNA siRNA
02
Targets
Innate immune RNA sensorsDANCR (Differentiation antagonizing non-protein coding RNA)
Beyond the preview
Go deeper on DANCR siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DANCR siRNA.